Abstract
Candida albicans is an opportunistic pathogenic fungus capable of causing infections in an expanding population of immunosuppressed patients. The implementation of proteomics in the post-genomic era of this organism can provide vital information about its biological complexity and pathogenic traits. C. albicans proteomic analyses to date have focused on the understanding of the cell wall, virulence, dimorphism, antifungal drug effects and resistance, and serological response, among others. This exciting and rapid growing discipline should become an indispensable tool in C. albicans research, particularly to address problems that cannot be solved by genomic studies. Furthermore, in the near future it is expected that results from proteomic experiments will lead to novel techniques for the management of candidiasis.
Keywords: Candida albicans, two-dimensional electrophoresis, proteomics, serology, cell wall, immunoproteomics, adhesins, morphogenesis, antifungal resistance
Infectious Disorders - Drug Targets
Title: Proteomics to Study Candida albicans Biology and Pathogenicity
Volume: 6 Issue: 4
Author(s): Derek P. Thomas, Aida Pitarch, Lucia Monteoliva, Concha Gil and Jose L. Lopez-Ribot
Affiliation:
Keywords: Candida albicans, two-dimensional electrophoresis, proteomics, serology, cell wall, immunoproteomics, adhesins, morphogenesis, antifungal resistance
Abstract: Candida albicans is an opportunistic pathogenic fungus capable of causing infections in an expanding population of immunosuppressed patients. The implementation of proteomics in the post-genomic era of this organism can provide vital information about its biological complexity and pathogenic traits. C. albicans proteomic analyses to date have focused on the understanding of the cell wall, virulence, dimorphism, antifungal drug effects and resistance, and serological response, among others. This exciting and rapid growing discipline should become an indispensable tool in C. albicans research, particularly to address problems that cannot be solved by genomic studies. Furthermore, in the near future it is expected that results from proteomic experiments will lead to novel techniques for the management of candidiasis.
Export Options
About this article
Cite this article as:
Thomas P. Derek, Pitarch Aida, Monteoliva Lucia, Gil Concha and Lopez-Ribot L. Jose, Proteomics to Study Candida albicans Biology and Pathogenicity, Infectious Disorders - Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/187152606779025815
DOI https://dx.doi.org/10.2174/187152606779025815 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Implication of microRNAs in the Pathogenesis of MDS
Current Pharmaceutical Design TRPA1 and TRPM8 Receptors May Promote Local Vasodilation that Aggravates Oxaliplatin-Induced Peripheral Neuropathy Amenable to 17β-Estradiol Treatment
Current Neurovascular Research Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry Intracoronary Injection of Drugs to Treat No – Reflow Phenomenon and Microcirculatory Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Combined Modality Treatment of Glioblastoma Multiforme: The Role of Temozolomide
Reviews on Recent Clinical Trials Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design Significance of CD34 Negative Hematopoietic Stem Cells and CD34 Positive Mesenchymal Stem Cells – A Valuable Dimension to the Current Understanding
Current Stem Cell Research & Therapy Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Tyrosine Kinase Inhibitors
Current Cancer Drug Targets Pharmacokinetics, Organ Toxicity and Antitumor Activity of Docetaxel Loaded in Folate Targeted Cholesterol Based Micelles
Current Drug Delivery Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy
Current Cancer Drug Targets Medication-Induced Nephrotoxicity in Older Patients
Current Drug Metabolism Subject Index To Volume 7
Current Pharmaceutical Biotechnology Epivention: Epigenetic Based Cancer Chemoprevention
Epigenetic Diagnosis & Therapy (Discontinued) Erythropoietin in Cancer: An Update
Current Molecular Medicine The Clinical Characteristics and Survival Profiles of Wilms Tumor in the United Arab Emirates: A Single-center Retrospective Analysis
New Emirates Medical Journal Inhibition of PI3K/Akt Signaling: An Emerging Paradigm for Targeted Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) 99mTechnetium- or Cy7-Labeled Fab(Tocilizumab) as Potential Multiple Myeloma Imaging Agents
Anti-Cancer Agents in Medicinal Chemistry Prevention of Immune-mediated Transfusion-related Acute Lung Injury; from Bloodbank to Patient
Current Pharmaceutical Design